The Crohn’s & Colitis Foundation has received a $1 million donation from the Wilbur May Foundation, an organization dedicated to the welfare of youth in the greater San Diego region and nationwide.
he Crohn’s & Colitis Foundation has joined forces with life science company Evotec SE, to help advance drug discovery for two innovative drug targets stemming from cutting-edge academic research for inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis.
Christy DeSantis, an accomplished marketing executive, begins her tenure today as the Chief Marketing & Communications Officer at the Crohn’s & Colitis Foundation. Tasked with steering the Foundation’s marketing and communications strategies, DeSantis joins the senior leadership team, playing a crucial role in shaping impactful initiatives across the organization.
The Crohn’s & Colitis Foundation, the nation’s leading nonprofit organization focused on research and patient support for inflammatory bowel disease (IBD), is joining forces with the Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) to increase awareness of opportunities for accessing some reduced-price essential IBD medications.
Alan Moss, MD, a renowned clinician-scientist, begins his tenure today as the Chief Scientific Officer at the Crohn’s & Colitis Foundation. His prior roles include serving as the Director of the Crohn’s & Colitis Program at Boston Medical Center (BMC) and Professor of Medicine at Boston University (BU). In his clinical practice, Dr. Moss has cared for IBD patients from underserved, immigrant, and unhoused populations.
September 25, 2023
Browser not supported
Your Internet Explorer is outdated. For optimal security settings and a better experience on our site, try switching to one of these options: